CBAY - FDA expands breakthrough status for CymaBay's seladelpar
2023-10-23 10:59:11 ET
More on CymaBay Therapeutics
- CymaBay: Positive Phase 3 Data And Competitive Advantage Established
- CymaBay Therapeutics: Shares Jump On Confirmatory Seladelpar Data - As Good As It Gets?
- CymaBay Therapeutics, Inc. (CBAY) Q2 2023 Earnings Call Transcript
- CymaBay says liver disease candidate outperformed in Phase 3 trial
- UBS starts Cymabay at buy, expecting positive Phase 3 data for seladelpar
For further details see:
FDA expands breakthrough status for CymaBay's seladelpar